{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838bv1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Strong","contributions":[{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838b_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10060","date":"2023-03-03T17:00:00.000Z","role":"Approver"},{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838b_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10060","date":"2023-03-03T17:05:53.053Z","role":"Publisher"}],"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/29100095","type":"dc:BibliographicResource","dc:abstract":"Approximately one in every 200 mammalian proteins is anchored to the cell membrane through a glycosylphosphatidylinositol (GPI) anchor. These proteins play important roles notably in neurological development and function. To date, more than 20 genes have been implicated in the biogenesis of GPI-anchored proteins. GPAA1 (glycosylphosphatidylinositol anchor attachment 1) is an essential component of the transamidase complex along with PIGK, PIGS, PIGT, and PIGU (phosphatidylinositol-glycan biosynthesis classes K, S, T, and U, respectively). This complex orchestrates the attachment of the GPI anchor to the C terminus of precursor proteins in the endoplasmic reticulum. Here, we report bi-allelic mutations in GPAA1 in ten individuals from five families. Using whole-exome sequencing, we identified two frameshift mutations (c.981_993del [p.Gln327Hisfs","dc:creator":"Nguyen TTM","dc:date":"2017","dc:title":"Mutations in GPAA1, Encoding a GPI Transamidase Complex Protein, Cause Developmental Delay, Epilepsy, Cerebellar Atrophy, and Osteopenia."},"evidence":[{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:ae65c917-7d70-4616-9a97-6167f246384f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ae65c917-7d70-4616-9a97-6167f246384f","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":8,"allele":[{"id":"cggv:68e844a0-4d56-445f-8060-cf8f7ae7cd91","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.947C>T (p.Ala316Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4932979"}},{"id":"cggv:12491c54-3b61-4035-b4cc-4957cc311046","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.1233_1239del (p.Pro412TyrfsTer19)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573332227"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DD/ID, Hypotonia, Seizures, Cerebellar atrophy, spasticity, nystagmus, Dysmorphic- Epicanthal folds, upslanting palpebral fissures, tented upper lip, and flat nasolabial folds","sex":"Female","variant":[{"id":"cggv:244d8fed-caf4-4b30-ac25-d0012658ef1c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:68e844a0-4d56-445f-8060-cf8f7ae7cd91"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/34703884","type":"dc:BibliographicResource","dc:abstract":"To expand the clinical knowledge of ","dc:creator":"Castle AMR","dc:date":"2021","dc:title":"Expanding the Phenotypic Spectrum of GPI Anchoring Deficiency Due to Biallelic Variants in "}},{"id":"cggv:311c4ed5-5166-4af1-a946-ee2c2f4c769b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12491c54-3b61-4035-b4cc-4957cc311046"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/34703884"}],"rdfs:label":"Patient 5"},{"id":"cggv:311c4ed5-5166-4af1-a946-ee2c2f4c769b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:311c4ed5-5166-4af1-a946-ee2c2f4c769b_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:244d8fed-caf4-4b30-ac25-d0012658ef1c","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:244d8fed-caf4-4b30-ac25-d0012658ef1c_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:6c032188-6110-41da-a571-7474e9796a96_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:6c032188-6110-41da-a571-7474e9796a96","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":3,"allele":[{"id":"cggv:5425525f-51cc-44f8-995b-66ddc0d1ca9c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.1559T>G (p.Leu520Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372506826"}},{"id":"cggv:b77b535f-a585-4287-a6e2-5de7a16e5f14","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.917A>G (p.His306Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372498886"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DD/ID, Hypotonia, Seizures, Cerebellar atrophy, spasticity, Dysmorphic- Prominent forehead, deep set eyes, downslanting PFs, small chin, and tented upper lip. Plasma ALP low","sex":"Female","variant":[{"id":"cggv:b267d20b-fcf4-4a0e-93b4-1b47b092bf11_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:5425525f-51cc-44f8-995b-66ddc0d1ca9c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/34703884"},{"id":"cggv:76598942-d103-4a6c-b03c-6238a4d4a38b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b77b535f-a585-4287-a6e2-5de7a16e5f14"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/34703884"}],"rdfs:label":"Patient 3"},{"id":"cggv:b267d20b-fcf4-4a0e-93b4-1b47b092bf11","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:b267d20b-fcf4-4a0e-93b4-1b47b092bf11_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:76598942-d103-4a6c-b03c-6238a4d4a38b","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:76598942-d103-4a6c-b03c-6238a4d4a38b_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:e523e322-86d4-4e3d-aa15-709da52de157_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e523e322-86d4-4e3d-aa15-709da52de157","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":12,"allele":[{"id":"cggv:e977ba5e-e7f0-4d90-9dae-337f6269cce7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.619del (p.Met207CysfsTer21)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4932889"}},{"id":"cggv:50b49a54-0dbb-4bc3-96ca-90831811d4b8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.149T>A (p.Met50Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4932724"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DD/ID, Hypotonia, Seizures, ataxia","sex":"Male","variant":[{"id":"cggv:a3742e78-5725-4536-b0e8-bff3efa4eba2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:50b49a54-0dbb-4bc3-96ca-90831811d4b8"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/34703884"},{"id":"cggv:92c22753-fc3f-43df-97bf-5484af5cbc27_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e977ba5e-e7f0-4d90-9dae-337f6269cce7"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/34703884"}],"rdfs:label":"Patient 7"},{"id":"cggv:92c22753-fc3f-43df-97bf-5484af5cbc27","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:92c22753-fc3f-43df-97bf-5484af5cbc27_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:a3742e78-5725-4536-b0e8-bff3efa4eba2","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:a3742e78-5725-4536-b0e8-bff3efa4eba2_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3f1aece4-f707-4924-bc13-b5a5863df29c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3f1aece4-f707-4924-bc13-b5a5863df29c","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":11,"allele":[{"id":"cggv:d9d325af-d357-4382-8cf0-ae083eb5d7e9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.920del (p.Gly307AlafsTer11)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658657835"}},{"id":"cggv:2a18483c-341f-4aca-ba68-9a8a2cc1e980","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.1165G>C (p.Ala389Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372502014"}}],"firstTestingMethod":"Genotyping","phenotypeFreeText":"DD/ID, Hypotonia, Seizures, Cerebellar atrophy, Nystagmus, Dysarthria, Spasticity, Osteopenia, dysmorphism- bitemporal narrowing, widely spaced eyes, prominent ears","previousTesting":false,"sex":"Female","variant":[{"id":"cggv:0ae8b2aa-d573-474e-977b-c65d48c40372_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d9d325af-d357-4382-8cf0-ae083eb5d7e9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095"},{"id":"cggv:b3e8a6d6-b9cb-402c-abae-3b1b9e4ec6db_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2a18483c-341f-4aca-ba68-9a8a2cc1e980"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095"}],"rdfs:label":"Family 3-individual 3a"},{"id":"cggv:b3e8a6d6-b9cb-402c-abae-3b1b9e4ec6db","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:b3e8a6d6-b9cb-402c-abae-3b1b9e4ec6db_variant_evidence_item"},{"id":"cggv:b3e8a6d6-b9cb-402c-abae-3b1b9e4ec6db_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Functional effect was tested by transfecting GPAA1-knockout HEK293 cells. p.Ala389Pro Variant showed reduced activity. Western blot of cell lysates showed the p.Ala389Pro variant, located in the second transmembrane domain, leads to protein instability."}],"strengthScore":0.5},{"id":"cggv:0ae8b2aa-d573-474e-977b-c65d48c40372","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:0ae8b2aa-d573-474e-977b-c65d48c40372_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f06e1391-eeb0-4d7d-a5da-383172107fd1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f06e1391-eeb0-4d7d-a5da-383172107fd1","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":5,"allele":[{"id":"cggv:15694dab-0eef-468e-b289-5023e41f70a0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.869T>C (p.Leu290Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372498194"}},{"id":"cggv:9ec64553-2703-4830-8e7a-a2e2c700bf57","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.160_161delinsAA (p.Ala54Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658657840"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DD/ID, Hypotonia, Cerebellar atrophy, Dysarthria, Dysmetria, Ataxic gait","previousTesting":false,"sex":"Male","variant":[{"id":"cggv:ddc5c067-dae3-4647-b0dd-a8c9255295d8_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9ec64553-2703-4830-8e7a-a2e2c700bf57"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095"},{"id":"cggv:075e1f81-3543-4ec2-960d-9ef1d7ed8cc0_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:15694dab-0eef-468e-b289-5023e41f70a0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095"}],"rdfs:label":"Family 5-individual 5a"},{"id":"cggv:075e1f81-3543-4ec2-960d-9ef1d7ed8cc0","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:075e1f81-3543-4ec2-960d-9ef1d7ed8cc0_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:ddc5c067-dae3-4647-b0dd-a8c9255295d8","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:ddc5c067-dae3-4647-b0dd-a8c9255295d8_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a6eaf12f-c8ba-4895-886d-b8b5c5cd137e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a6eaf12f-c8ba-4895-886d-b8b5c5cd137e","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"allele":[{"id":"cggv:395aeef3-3812-4bfc-ba21-134d4ff8f9ba","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.981_993del (p.Gln327HisfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658657836"}},{"id":"cggv:439b085a-1a55-4df1-a7d3-9e332a2af4ca","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.872T>C (p.Leu291Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA187609888"}}],"ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Developmental delay/ intellectual disability, hypotonia, seizures, cerebellar atrophy, nystagmus, dysmetria, ataxic gait, osteopenia","previousTesting":false,"sex":"Female","variant":[{"id":"cggv:acfcfaa7-e89b-481a-b5fc-7449faa25bda_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:439b085a-1a55-4df1-a7d3-9e332a2af4ca"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095"},{"id":"cggv:df42de8c-7873-4d6f-9999-eaa06f970bb0_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:395aeef3-3812-4bfc-ba21-134d4ff8f9ba"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095"}],"rdfs:label":"Family 1-individual 1a"},{"id":"cggv:df42de8c-7873-4d6f-9999-eaa06f970bb0","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:df42de8c-7873-4d6f-9999-eaa06f970bb0_variant_evidence_item"},{"id":"cggv:df42de8c-7873-4d6f-9999-eaa06f970bb0_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"RT PCR on both fibroblasts and LCLs of individuals 1a and 1b demonstrated that c.981_993del variant introduces a stop codon at amino acid 428 (p.Gln327Hisfs*102). "}],"strengthScore":1.5,"dc:description":"Functional evidence confirms LoF"},{"id":"cggv:acfcfaa7-e89b-481a-b5fc-7449faa25bda","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:acfcfaa7-e89b-481a-b5fc-7449faa25bda_variant_evidence_item"},{"id":"cggv:acfcfaa7-e89b-481a-b5fc-7449faa25bda_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"In GPAA1-deficient HEK 293 cells, mutant activity was not significantly reduced compared to WT and overexpression experiment showed sufficient residual activity to provide a rescue."}],"strengthScore":0.1,"dc:description":"Reduced points since protein activity is not significantly reduced."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5648c6ed-da6f-43ba-be91-ccc0758f918f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5648c6ed-da6f-43ba-be91-ccc0758f918f","type":"Proband","ageType":"AgeAtReport","ageUnit":"Months","ageValue":22,"allele":[{"id":"cggv:6c23a021-e315-43eb-8529-d2ce344013a8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.1477_1478del (p.Arg493GlyfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4933184"}},{"id":"cggv:4600d12f-5ebc-448a-bd71-c6b9a011fab9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.1831T>C (p.Trp611Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372509985"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DD/ID, Hypotonia, Seizures, Dysmorphic- Single palmar crease","sex":"Male","variant":[{"id":"cggv:5b51c018-0d23-4247-8a8c-4dfa07ea6fe6_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4600d12f-5ebc-448a-bd71-c6b9a011fab9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/34703884"},{"id":"cggv:c096c3b3-f200-46ee-bb1a-705076692015_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:6c23a021-e315-43eb-8529-d2ce344013a8"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/34703884"}],"rdfs:label":"Patient 6"},{"id":"cggv:5b51c018-0d23-4247-8a8c-4dfa07ea6fe6","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:5b51c018-0d23-4247-8a8c-4dfa07ea6fe6_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:c096c3b3-f200-46ee-bb1a-705076692015","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:c096c3b3-f200-46ee-bb1a-705076692015_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:9d967667-c492-4b3c-aacf-d9119204a650_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:9d967667-c492-4b3c-aacf-d9119204a650","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"allele":[{"id":"cggv:a1cc2635-b9fa-4468-a4bc-0fbbf5b1de0a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.1164+5C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4933063"}},{"id":"cggv:c9a52f71-6ad4-45d8-9d7a-c3a28f05e65e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003801.4(GPAA1):c.152C>T (p.Ser51Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372597515"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Developmental delay/ID, hypotonia, seizures, cortical visual impairment, osteopenia, dysmorphism- bitemporal narrowing, prominent forehead, antereveted nares","previousTesting":false,"sex":"Male","variant":[{"id":"cggv:a855bf9e-4460-409d-bf7d-32e995cc246d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a1cc2635-b9fa-4468-a4bc-0fbbf5b1de0a"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095"},{"id":"cggv:9ce3aea3-0bca-44e0-9ce9-ff57566bfd18_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c9a52f71-6ad4-45d8-9d7a-c3a28f05e65e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095"}],"rdfs:label":"Family 2-individual 2"},{"id":"cggv:a855bf9e-4460-409d-bf7d-32e995cc246d","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:a855bf9e-4460-409d-bf7d-32e995cc246d_variant_evidence_item"},{"id":"cggv:a855bf9e-4460-409d-bf7d-32e995cc246d_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"the intronic splicing variant c.1164+5C>T showed decreased mRNA expression of GPAA1 in LCLs. Splice AI predicts its acts as donor loss (score :0.75)"}],"strengthScore":0.5},{"id":"cggv:9ce3aea3-0bca-44e0-9ce9-ff57566bfd18","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9ce3aea3-0bca-44e0-9ce9-ff57566bfd18_variant_evidence_item"},{"id":"cggv:9ce3aea3-0bca-44e0-9ce9-ff57566bfd18_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"GPAA1-knockout cells were transiently transfected with a plasmid encoding wild-type or variant. Decreased activity was noted for the p.Ser51-Leu variant compared to WT. "}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838b_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":9.8}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":9.8},{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838b_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:94ee0b43-6f61-4443-a35f-98ee254b4109","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:dac0ef93-bb07-473f-a32b-9e38a6483008","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"This study used CHO cells to evaluate the the role of the different components in the GPI transamidase complex. In cells transfected with all components, FLAG-GAA1 co-precipitated Myc-PIG-T, haemagglutinin (HA)-PIG-S and GST–GPI8 (also known as PIGK). In the absence of transfection of GAA1, three other components were expressed well and one component co-precipitated with the other two components. In the absence of PIG-T transfection, expression of FLAG- GAA1 was markedly decreased. PIGS: glycosylphosphatidylinositol biosynthesis defect 18.\n(Also see PMID 12802054 for PIGU).  A total of five genes of the GPI transamidase complex have been associated with human disease (GPI deficiency). Not curated by ClinGen; GenCC2 x strong assertions (PanelAppAustralia, Invitae) one Moderate assertion (Invitae) PIGT: multiple congenital anomalies-hypotonia-seizures syndrome 3 Not curated by ClinGen; GenCCDefinitive (TGMI), 3 x Strong assertions (PanelAppAustralia, Invitae, Ambry). PIGK: neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures Not curated by ClinGen; 2 x Strong assertions (PanelAppAustralia, Invitae,) Moderate (Ambry). PIGU- Limited by ClinGen.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/11483512","type":"dc:BibliographicResource","dc:abstract":"Many eukaryotic cell surface proteins are anchored to the plasma membrane via glycosylphosphatidylinositol (GPI). The GPI transamidase mediates GPI anchoring in the endoplasmic reticulum, by replacing a protein's C-terminal GPI attachment signal peptide with a pre-assembled GPI. During this transamidation reaction, the GPI transamidase forms a carbonyl intermediate with a substrate protein. It was known that the GPI transamidase is a complex containing GAA1 and GPI8. Here, we report two new components of this enzyme: PIG-S and PIG-T. To determine roles for PIG-S and PIG-T, we disrupted these genes in mouse F9 cells by homologous recombination. PIG-S and PIG-T knockout cells were defective in transfer of GPI to proteins, particularly in formation of the carbonyl intermediates. We also demonstrate that PIG-S and PIG-T form a protein complex with GAA1 and GPI8, and that PIG-T maintains the complex by stabilizing the expression of GAA1 and GPI8. Saccharomyces cerevisiae Gpi16p (YHR188C) and Gpi17p (YDR434W) are orthologues of PIG-T and PIG-S, respectively.","dc:creator":"Ohishi K","dc:date":"2001","dc:title":"PIG-S and PIG-T, essential for GPI anchor attachment to proteins, form a complex with GAA1 and GPI8."},"rdfs:label":"GPI transamidase complex"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"cggv:b3febee5-7fb9-4427-a876-df7a00733a29","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:1a0e222b-dd87-4236-bc24-89903e0fafba","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionA"},"dc:description":"GPI biosynthetic pathway includes a group of enzymes that form the GPI transamidase complex. Defects in 13 additional genes GPI biosynthetic pathway (besides the transamidase complex) result in clinically similar phenotype (GPI biosynthesis disorders). PIGA (MIM: 311770) - Moderate (ICSL); PIGM (MIM: 610273) - Limited (TGMI); PIGL (MIM:605947)- Definitive (TGMI); PIGW (MIM: 610275)- Moderate (Ambry); PIGV (MIM: 610274) - Definitive (TGMI); PIGO (MIM:610274)- Strong (ICSL); PIGN (MIM: 606097) – Strong (TGMI); PIGC (MIM: 601730) – Limited (Ambry); PIGP (MIM:605938) - Moderate (Ambry); PIGG (MIM: 616918) – Strong (Invitae); PGAP1 [MIM:611655] – Strong (Invitae); PGAP2 [MIM: 615187] - Definitive (TGMI); PGAP3 (MIM:615716) – Definitive (TGMI)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095","rdfs:label":"GPI biosynthesis pathway"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1,"dc:description":"Increased from default based on the number of genes involved in the GPI pathway that are associated with the same phenotype."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838b_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:cd2b2658-cf3a-4ef8-86a6-c8b629912be6","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:e7aa9e38-eec4-4185-b71f-a0af6451642b","type":"FunctionalAlteration","dc:description":"Flow-cytometry analysis showed GPI-AP deficiency in patient cells (granulocytes). CD16 and CD24 expression was reduced. GPI cell-surface markers (FLAER, CD73, and CD109) were assessed on the cell surface of skin fibroblasts. All three were variably downregulated in different patient cells. Rescue assays on fibroblasts from the patient showed that CD109 was completely rescued in fibroblasts while CD73 was only partially rescued. Patient cells show GPI-AP deficiency and GPI cell-surface marker downregulation in fibroblasts.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29100095","rdfs:label":"GPI-AP deficiency in patient cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0.5,"dc:description":"Evidence is variable in cells from different patients (not strong evidence)."}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Strong","sequence":5933,"specifiedBy":"GeneValidityCriteria9","strengthScore":11.8,"subject":{"id":"cggv:bc809f45-f20a-43d7-8385-578878758485","type":"GeneValidityProposition","disease":"obo:MONDO_0060627","gene":"hgnc:4446","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"The GPAA1 gene is located on chromosome 8 at 8q24.3 and encodes the glycosylphosphatidylinositol anchor attachment 1, a ubiquitously expressed protein which is a component of the glycosylphosphatidylinositol (GPI) transamidase complex that mediates coupling of the synthesized GPI anchor to mature proteins on the cell surface. GPI anchor proteins are structurally a diverse group of membrane bound glycoproteins that play an important role in cellular processes such as embryogenesis, fertilization, and neurogenesis. The GPAA1 gene was first reported in relation to autosomal recessive glycosylphosphatidylinositol biosynthesis defect 15 in 2017 (Nguyen et al., 2017 PMID 29100095) and is characterized by delayed psychomotor development, variable intellectual disability, hypotonia, early-onset seizures in most patients, and cerebellar atrophy resulting in gait ataxia and dysarthria. Evidence supporting this gene-disease relationship includes case-level data, segregation data, and experimental data. At least 16 unique variants have been reported in either a compound heterozygous or homozygous state in 8 probands from two publications (PMID 29100095; Castle et al., 2021 PMID: 34703884). These included 10 missense variants, five frameshift variants, and one intronic variant shown to affect splicing.  Variants in this gene segregate with disease in five families. More genetic evidence has been reported in the literature but was not scorable according to the current guideline. This gene-disease relationship is supported by relevant experimental evidence including biochemical function, protein interaction, and functional alteration in patient cells. A number of genes involved in the biosynthesis of the GPI anchor have been associated with GPI biosynthesis deficiencies, characterized by a clinical spectrum of disease which includes global developmental delay, intellectual disability, and seizures (PMID 29100095). Specifically, four components of the GPI transamidase complex; PIGT, PIGS, PIGK, and PIGU have been shown to interact with each other and have all been associated with autosomal recessive glycosylphosphatidylinositol biosynthesis deficiencies (Ohishi K et al., 2001 PMID 11483512; Bellai-Dussault et al., 2018 PMID 30054924; Hong Y et al., 2003 PMID 12802054). Patient cells demonstrate GPI-AP deficiency and altered expression of cell surface markers on the cell surface of skin fibroblasts (PMID 29100095). In summary, there is strong evidence to support this gene-disease relationship. Three years must elapse from the first proposal of the association to reach a definitive classification without any valid contradictory evidence. We will re-evaluate this gene-disease relationship at that time to determine if an upgraded classification of definitive is warranted.. This classification was approved by the ClinGen Syndromic Disorders Gene Curation Expert Panel on the meeting date 12/07/2022 (SOP Version 9.0). ","dc:isVersionOf":{"id":"cggv:682c38ac-9075-47ec-96e4-cc2ce7b0838b"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}